InscoBee Appoints Eric Emerson Apimez as CEO of US Branch, the 'Midas Touch'

InscoBio, a KOSPI-listed company, announced on the 10th that it has appointed Erik Emerson, a bio investment attraction expert, as the new CEO of its subsidiary Apimez's U.S. branch.

With this CEO appointment, Apimez's U.S. branch plans to focus on attracting investments to accelerate the Phase 3 clinical trial of its multiple sclerosis (MS) treatment candidate, Apitox, with the U.S. FDA. On the 26th of last month, the company announced that it had completed a capital increase through debt-to-equity conversion and paid-in capital increase to strengthen its primary capital for Apitox's U.S. Phase 3 trial.

Erik Emerson, the new CEO of Apimez's U.S. branch, is an expert with extensive experience in the rare disease field and a broad network with investment banks. He is especially recognized for his outstanding ability in funding and establishing revenue models.

From 2013 to 2018, he served as CEO of the U.S. pharmaceutical company Symplmed Pharmaceuticals & Technologies. He successfully raised a total capital of $10 million (approximately KRW 16.3 billion) to develop the hypertension drug Prestalia and launch the medical technology platform DyrctAxess.

In 2018, he sold the patents for Prestalia and DyrctAxess to the U.S. company Adhera Therapeutics. He then participated as a board member of Adhera Therapeutics to complete the related projects.

Afterward, in 2022, Erik Emerson served as a management advisor at Odyssey Neuropharma, providing consulting across all areas including commercial strategy, forecasting, branding, marketing, and fundraising in preparation for Phase 2 trials related to concussion treatment. He completed human safety studies for ONP002 (a neurosteroid for severe concussion treatment), advancing ahead of competitors and led a $15 million (approximately KRW 20.4 billion) fundraising strategy.

Erik Emerson, CEO of Apimez's U.S. branch, stated, “I have accumulated various successful experiences and attracted investments in the bio industry over the past 20 years. Based on my experience so far, I will actively lead the Phase 3 progress of Apimez's U.S. branch.”

An InscoBio official said, “Erik Emerson is a strategist who has held key positions at global major pharmaceutical and biotech companies, leading successful business model development and growth. We expect that the new CEO’s abundant experience and know-how in attracting investments will create great synergy with Apimez’s new drug development business.”